Why Bristol Myers Squibb Deserves a Place in Your Portfolio

Anirudh Shankar, The Motley Fool
·4-min read
Why Bristol Myers Squibb Deserves a Place in Your Portfolio

One particularly notable sale-priced company in the sector is the pharmaceutical giant Bristol Myers Squibb (NYSE: BMY) The company has recently made acquisitions, increased dividends, and launched a new share buyback program, making 2021 a great time to buy in. Bristol Myers Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn. The company has been at the forefront of contributions to medicine ever since, bringing the world blockbuster drugs such as Coumadin (blood thinners), Orencia (for rheumatoid arthritis), and many more.